Category: 819867-21-5

Related Products of 819867-21-5, An article , which mentions 819867-21-5, molecular formula is C22H31O2P. The compound – Di-tert-butyl(2′,6′-dimethoxy-[1,1′-biphenyl]-2-yl)phosphine played an important role in people’s production and life.

PROTEIN KINASE INHIBITORS (VARIANTS), USE THEREOF IN TREATING ONCOLOGICAL DISEASES AND A PHARMACEUTICAL COMPOSITION BASED THEREON

The present invention relates to the treatment of oncological, chronic inflammatory and similar diseases with the aid of new families of chemical compounds having improved efficiency with regard to the inhibition of Abl kinase and mutant forms thereof, as well as other therapeutically significant kinases. It describes protein kinase inhibitors in the form of compounds of general formula (I) and compounds of general formula (II), or a tautomer, an individual isomer, a mixture of isomers, a pharmaceutically acceptable salt, a solvate or a hydrate thereof.

I hope this article can help some friends in scientific research. I am very proud of our efforts over the past few months and hope to 819867-21-5, help many people in the next few years., Related Products of 819867-21-5

Reference£º
Phosphine ligand,
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate

819867-21-5,819867-21-5, Di-tert-butyl(2′,6′-dimethoxy-[1,1′-biphenyl]-2-yl)phosphine is a chiral-phosphine-ligands compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

3-((1H-benzimidazol-1-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide Copper (I) iodide (396 mg, 4 mol.%) is added to a suspension of iododerivative (26.9 g, 52 mmol) and 1-ethynyl-1H-benzimidazole (7.4 g, 52 mmol) in a mixture of degassed dry triethylamine (100 ml) and degassed dry THF (40 ml) and the reaction mixture is stirred for 10 min. Pd(Ph3P)2Cl2 (730 mg, 2 mol.%), PPh3 (1.1 g) and di-tert-butyl(2′,6′-dimethoxybiphenyl-2-yl)phosphine (100 mg) are then added, the reaction mixture is degassed twice and stirred at 65C for 80 h under inert atmosphere. Solvents are evaporated and the residue is purified chromatographically, using chloroform:methanol mixture of increasing polarity, yielding the desired product (13 g, 47%).

As the paragraph descriping shows that 819867-21-5 is playing an increasingly important role.

Reference£º
Patent; Obshchestvo S Ogranichennoy Otvetstvennostyou “Fusion Pharma”; CHILOV, Germes Grigorievich; TITOV, Ilya Yurievich; EP2743266; (2014); A2;,
Phosphine ligand
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate

819867-21-5,819867-21-5, Di-tert-butyl(2′,6′-dimethoxy-[1,1′-biphenyl]-2-yl)phosphine is a chiral-phosphine-ligands compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

3-([1,2,4]triazolo[4,3-a]pyridin-3-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide Copper (I) iodide (396 mg, 4 mol.%) is added to a suspension of acetylene derivative (21.6 g, 52 mmol) and 3-bromo-[1,2,4]triazolo[4,3-b]pyridine (10.3 g, 52 mmol) in a mixture of degassed dry triethylamine (100 ml) and degassed dry THF (40 ml) and the reaction mixture is stirred for 10 min. Pd(Ph3P)2Cl2 (730 mg, 2 mol.%), PPh3 (1.1 g) and di-tert-butyl(2′,6′-dimethoxybiphenyl-2-yl)phosphine (100 mg) are then added, the reaction mixture is degassed twice and stirred at 65C for 80 h under inert atmosphere. Solvents are evaporated and the residue is purified chromatographically, using chloroform:methanol mixture of increasing polarity, yielding the desired product (10.2 g, 37%).

819867-21-5 Di-tert-butyl(2′,6′-dimethoxy-[1,1′-biphenyl]-2-yl)phosphine 67475893, achiral-phosphine-ligands compound, is more and more widely used in various fields.

Reference£º
Patent; Obshchestvo S Ogranichennoy Otvetstvennostyou “Fusion Pharma”; CHILOV, Germes Grigorievich; TITOV, Ilya Yurievich; EP2743266; (2014); A2;,
Phosphine ligand
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate

819867-21-5,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.819867-21-5,Di-tert-butyl(2′,6′-dimethoxy-[1,1′-biphenyl]-2-yl)phosphine,as a common compound, the synthetic route is as follows.

Potassium 3-((2-methyl-5-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenylcarbamoyl)phenyl)ethynyl)-[1,2,4]triazolo[4,3-a]pyridine-7-carboxylate Copper (I) iodide (396 mg, 4 mol.%) is added to a suspension of acetylene derivative (21.6 g, 52 mmol) and ethyl 3-bromo[1,2,4]triazolo[4,3-b]pyridine-7-carboxylate (14.0 g, 52 mmol) in a mixture of degassed dry triethylamine (100 ml) and degassed dry THF (40 ml) and the reaction mixture is stirred for 10 min. Pd(Ph3P)2Cl2 (730 mg, 2 mol.%), PPh3 (1.1 g) and di-tert-butyl(2′,6′-dimethoxybiphenyl-2-yl)phosphine (100 mg) are then added, the reaction mixture is degassed twice and stirred at 65C for 130 h under inert atmosphere. Solvents are evaporated and the residue is purified chromatographically, using chloroform:methanol mixture of increasing polarity. The obtained product is dissolved in dry DMSO (50 ml). Water (1 ml) and potassium tert-butylate (0.6 g) are added and the mixture is stirred for 4 h. The desired product is purified on an ion exchange resin (15.1 g, 47%).

As the paragraph descriping shows that 819867-21-5 is playing an increasingly important role.

Reference£º
Patent; Obshchestvo S Ogranichennoy Otvetstvennostyou “Fusion Pharma”; CHILOV, Germes Grigorievich; TITOV, Ilya Yurievich; EP2743266; (2014); A2;,
Phosphine ligand
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate

819867-21-5,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.819867-21-5,Di-tert-butyl(2′,6′-dimethoxy-[1,1′-biphenyl]-2-yl)phosphine,as a common compound, the synthetic route is as follows.

Potassium 3-((2-methyl-5-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenylcarbamoyl)phenyl)ethynyl)-[1,2,4]triazolo[4,3-b]pyridazine-7-carboxylate Copper (I) iodide (396 mg, 4 mol.%) is added to a suspension of acetylene derivative (21.6 g, 52 mmol) and ethyl 3-bromo[1,2,4]triazolo[4,3-b]pyridazine-7-carboxylate (14.1 g, 52 mmol) in a mixture of degassed dry triethylamine (100 ml) and degassed dry THF (40 ml) and the reaction mixture is stirred for 10 min. Pd(Ph3P)2Cl2 (730 mg, 2 mol.%), PPh3 (1.1 g) and di-tert-butyl(2′,6′-dimethoxybiphenyl-2-yl)phosphine (100 mg) are then added, the reaction mixture is degassed twice and stirred at 65C for 130 h under inert atmosphere. Solvents are evaporated and the residue is purified chromatographically, using chloroform:methanol mixture of increasing polarity. The obtained product is dissolved in dry DMSO (50 ml). Water (1 ml) and potassium tert-butylate (0.6 g) are added and the mixture is stirred for 4 h. The desired product is purified on an ion exchange resin (16.3 g, 52%).

The synthetic route of 819867-21-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Obshchestvo S Ogranichennoy Otvetstvennostyou “Fusion Pharma”; CHILOV, Germes Grigorievich; TITOV, Ilya Yurievich; EP2743266; (2014); A2;,
Phosphine ligand
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate